NASDAQ:ARQT Arcutis Biotherapeutics (ARQT) Stock Price, News & Analysis $26.27 -0.39 (-1.46%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$26.71 +0.44 (+1.67%) As of 07:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcutis Biotherapeutics Stock (NASDAQ:ARQT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get ARQT alerts:Sign Up Key Stats Today's Range$26.18▼$27.1750-Day Range$19.50▼$26.6652-Week Range$13.06▼$31.77Volume1.66 million shsAverage Volume1.72 million shsMarket Capitalization$3.29 billionP/E RatioN/ADividend YieldN/APrice Target$34.00Consensus RatingModerate Buy Company Overview Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company’s research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options. In August 2022, Arcutis received U.S. Food and Drug Administration approval for ZORYVE™ (roflumilast) cream, the company’s first commercial product, indicated for the treatment of plaque psoriasis in adults. Arcutis is also advancing a pipeline of next-generation roflumilast formulations, including topical ointments and foams, for the treatment of atopic dermatitis and seborrheic dermatitis. Additional clinical-stage programs include selective kinase inhibitors and other small-molecule assets aimed at expanding the company’s portfolio of dermatology therapies. Founded in 2017 and headquartered in Westlake Village, California, Arcutis has built a U.S. specialty commercial infrastructure to support the launch and market adoption of its products. The company is led by President and Chief Executive Officer Steven L. Gothel, whose leadership team brings extensive experience in dermatology drug development, regulatory affairs and commercial operations. Arcutis continues to collaborate with academic investigators and patient advocacy groups to advance its clinical programs and address unmet needs in dermatology.AI Generated. May Contain Errors. Read More Arcutis Biotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreARQT MarketRank™: Arcutis Biotherapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 132nd out of 850 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingModerate Buy Consensus RatingArcutis Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 5 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialArcutis Biotherapeutics has a consensus price target of $34.00, representing about 29.4% upside from its current price of $26.27.Amount of Analyst CoverageArcutis Biotherapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Arcutis Biotherapeutics' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth540.00% Earnings GrowthEarnings for Arcutis Biotherapeutics are expected to grow by 540.00% in the coming year, from $0.15 to $0.96 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcutis Biotherapeutics is -875.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcutis Biotherapeutics is -875.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcutis Biotherapeutics has a P/B Ratio of 16.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arcutis Biotherapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted14.32% of the float of Arcutis Biotherapeutics has been sold short.Short Interest Ratio / Days to CoverArcutis Biotherapeutics has a short interest ratio ("days to cover") of 8.44.Change versus previous monthShort interest in Arcutis Biotherapeutics has recently decreased by 7.53%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcutis Biotherapeutics does not currently pay a dividend.Dividend GrowthArcutis Biotherapeutics does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.25 News SentimentArcutis Biotherapeutics has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Arcutis Biotherapeutics this week, compared to 6 articles on an average week.Search Interest12 people have searched for ARQT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows2 people have added Arcutis Biotherapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership1.1 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arcutis Biotherapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $968,886.00 in company stock.Percentage Held by Insiders9.40% of the stock of Arcutis Biotherapeutics is held by insiders.Percentage Held by InstitutionsArcutis Biotherapeutics has minimal institutional ownership at this time.Read more about Arcutis Biotherapeutics' insider trading history. Receive ARQT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcutis Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARQT Stock News HeadlinesArcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65%June 23 at 8:50 PM | finance.yahoo.comArcutis Biotherapeutics (NASDAQ:ARQT) Director Sells $16,300.45 in StockJune 18, 2026 | insidertrades.comBig Oil knew about this for 50 yearsIn the 1970s, Chevron, Unocal, and Texaco all drilled the same energy source - and walked away to protect oil profits. One company spent sixty years quietly proving them wrong. Now Google has signed a 15-year contract, Bill Gates has committed $100 million, and a July 4th government decision could hand this sector its biggest catalyst yet. The oil majors are scrambling back in, but one company already owns the entire chain.June 24 at 1:00 AM | Behind the Markets (Ad)Is Arcutis (ARQT) Using Genital Psoriasis Education to Quietly Reshape Its Dermatology Strategy?June 11, 2026 | finance.yahoo.comArcutis Biotherapeutics, Inc. (ARQT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9, 2026 | seekingalpha.comArcutis Stockholders Approve Proposals at 2026 MeetingJune 9, 2026 | tipranks.comArcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 5, 2026 | globenewswire.comNew Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical DermatologyJune 3, 2026 | globenewswire.comSee More Headlines ARQT Stock Analysis - Frequently Asked Questions How have ARQT shares performed this year? Arcutis Biotherapeutics' stock was trading at $29.04 at the beginning of 2026. Since then, ARQT stock has decreased by 9.5% and is now trading at $26.27. How were Arcutis Biotherapeutics' earnings last quarter? Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) issued its earnings results on Wednesday, May, 6th. The company reported ($0.09) earnings per share for the quarter, missing the consensus estimate of ($0.02) by $0.07. The firm earned $105.40 million during the quarter, compared to the consensus estimate of $103.68 million. Arcutis Biotherapeutics had a negative trailing twelve-month return on equity of 1.41% and a negative net margin of 0.57%. Read the conference call transcript. When did Arcutis Biotherapeutics IPO? Arcutis Biotherapeutics (ARQT) raised $150 million in an IPO on Friday, January 31st 2020. The company issued 9,375,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs, Cowen and Guggenheim Securities acted as the underwriters for the IPO and Cantor was co-manager. Who are Arcutis Biotherapeutics' major shareholders? Arcutis Biotherapeutics' top institutional shareholders include Jennison Associates LLC (3.98%), Bank of America Corp DE (1.78%), Janus Henderson Group PLC (1.48%) and Candriam S.C.A. (0.87%). Insiders that own company stock include Life Sciences Viii L Frazier, Todd Franklin Watanabe, Todd Watanabe, Larry Todd Edwards, David Joseph Topper, Masaru Matsuda, Patrick Burnett, Latha Vairavan, Howard G Welgus, Sue-Jean Lin, Patrick J Heron, Neha Krishnamohan, Halley E Gilbert and Terrie Curran. View institutional ownership trends. How do I buy shares of Arcutis Biotherapeutics? Shares of ARQT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcutis Biotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcutis Biotherapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Advanced Micro Devices (AMD), SPDR S&P 500 ETF Trust (SPY), Tesla (TSLA), Meta Platforms (META) and SPDR Dow Jones Industrial Average ETF Trust (DIA). Company Calendar Last Earnings5/06/2026Today6/24/2026Next Earnings (Estimated)8/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (22m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 ARQT's financial health is in the Green zone, according to TradeSmith. ARQT has been in this zone for over 22 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARQT CIK1787306 Webwww.arcutis.com Phone805-418-5006FaxN/AEmployees150Year Founded2016Price Target and Rating Average Price Target for Arcutis Biotherapeutics$34.00 High Price Target$36.00 Low Price Target$29.00 Potential Upside/Downside+29.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($0.03) Trailing P/E RatioN/A Forward P/E Ratio175.13 P/E GrowthN/ANet Income-$16.14 million Net Margins-0.57% Pretax Margin-0.33% Return on Equity-1.41% Return on Assets-0.59% Debt Debt-to-Equity Ratio0.54 Current Ratio2.68 Quick Ratio2.46 Sales & Book Value Annual Sales$376.07 million Price / Sales8.74 Cash FlowN/A Price / Cash FlowN/A Book Value$1.55 per share Price / Book16.95Miscellaneous Outstanding Shares125,080,000Free Float113,325,000Market Cap$3.29 billion OptionableOptionable Beta1.51 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:ARQT) was last updated on 6/24/2026 by MarketBeat.com Staff. From Our PartnersFour winners over 400%. Here's #5CFA and CMT analyst Garrett Goggin called G2 Goldfields before it rose 1,023%, Reunion Gold before 538%, Highl...Golden Portfolio | Sponsored25-Cent Gold Explorer Set to Drill Top Canadian Mineral BeltWith gold racing toward US$5,000 an ounce, one sub-$0.25 explorer is launching a fully funded drill campaign o...Resource Stock Digest | SponsoredMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredElon Musk, Larry Fink & Brian Armstrong are ALL Piling into ThisElon Musk, BlackRock CEO Larry Fink, and Coinbase CEO Brian Armstrong are all quietly investing in the same te...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcutis Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcutis Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
